Cargando…
Molecular and clinical features of a potential immunotherapy target ELK3 in glioma
Glioma represents the most prevalent malignant primary brain cancer, and its treatment remains a tremendous challenge. Novel and efficient molecular targets are therefore required for improving diagnosis, survival prediction, and treatment outcomes. Additionally, some studies have shown that immunit...
Autores principales: | Xu, Hao, Zhang, Li, Gao, Jin, Wang, Jiajing, Wang, Yihao, Xiao, Dongdong, Chai, Songshan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333475/ https://www.ncbi.nlm.nih.gov/pubmed/35905257 http://dx.doi.org/10.1097/MD.0000000000029544 |
Ejemplares similares
-
Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target
por: Xu, Hao, et al.
Publicado: (2020) -
Remodelling and Treatment of the Blood-Brain Barrier in Glioma
por: Wang, Yihao, et al.
Publicado: (2021) -
ELK3: A New Molecular Marker for the Diagnosis and Prognosis of Glioma
por: Liu, Zhendong, et al.
Publicado: (2021) -
The molecular feature of macrophages in tumor immune microenvironment of glioma patients
por: Zhang, Hao, et al.
Publicado: (2021) -
Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy
por: Li, Guan-Zhang, et al.
Publicado: (2019)